Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$83.30−4.45 (-5.07%)
Close on Nov 13, 2026Market cap $1.23BP/E –Yield –
Inhibrx Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Inhibrx Biosciences's profit margin for the twelve months ending Dec 31, 2025 was -10773.5%. For fiscal 2025 it was -10773.5%, against 843786.0% the year before. The highest annual figure on record is 843786.0% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -10773.5% | −854559.5 |
| FY2024 | Dec 31, 2024 | 843786.0% | +857194.9 |
| FY2023 | Dec 31, 2023 | -13408.9% | −6783.7 |
| FY2022 | Dec 31, 2022 | -6625.3% | −5494.5 |
| FY2021 | Dec 31, 2021 | -1130.8% | −540.1 |
| FY2020 | Dec 31, 2020 | -590.7% | −201.6 |
| FY2019 | Dec 31, 2019 | -389.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1936.6% | +3791.9 |
| Q2 FY2025 | Jun 30, 2025 | -2204.2% | +41316.0 |
| Q4 FY2024 | Dec 31, 2024 | -47865.0% | +108975.0 |
| Q2 FY2024 | Jun 30, 2024 | 1858011.0% | +2145752.2 |
| Q4 FY2023 | Dec 31, 2023 | -5728.5% | +9204.0 |
| Q3 FY2023 | Sep 30, 2023 | -43520.2% | −30813.3 |
| Q2 FY2023 | Jun 30, 2023 | -156840.0% | −151533.1 |
| Q1 FY2023 | Mar 31, 2023 | -287741.2% | −284376.9 |
| Q4 FY2022 | Dec 31, 2022 | -14932.5% | −14190.6 |
| Q3 FY2022 | Sep 30, 2022 | -12706.8% | −11894.0 |
| Q2 FY2022 | Jun 30, 2022 | -5306.9% | −3136.0 |
| Q1 FY2022 | Mar 31, 2022 | -3364.3% | −1194.5 |
| Q4 FY2021 | Dec 31, 2021 | -741.9% | −106.1 |
| Q3 FY2021 | Sep 30, 2021 | -812.8% | −465.4 |
| Q2 FY2021 | Jun 30, 2021 | -2170.9% | −1635.2 |
| Q1 FY2021 | Mar 31, 2021 | -2169.7% | +134.5 |
| Q4 FY2020 | Dec 31, 2020 | -635.8% | +5563.8 |
| Q3 FY2020 | Sep 30, 2020 | -347.3% | +1306.7 |
| Q2 FY2020 | Jun 30, 2020 | -535.6% | – |
| Q1 FY2020 | Mar 31, 2020 | -2304.2% | – |
| Q4 FY2019 | Dec 31, 2019 | -6199.6% | – |
| Q3 FY2019 | Sep 30, 2019 | -1654.1% | – |
See a number that looks wrong?